Investor Relations

Press Releases

Advaxis to Present at the Jefferies Immuno-Oncology Summit

Read More

Advaxis Announces First Patient Treated in Phase 1/2 Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer

Read More

Advaxis's Lm-LLO Immunotherapy Platform to be Featured in Three Poster Presentations at the 2015 American Association for Cancer Research Annual Meeting

Read More

Advaxis Presents Preliminary Data From a Phase 1/2 Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combination With Chemoradiation Showing Complete Response and No Recurrences to Date in All Treated Patients

Read More

Gynecologic Oncology Group (GOG) Commences Enrollment in Stage 2 of GOG-0265 Clinical Trial

Read More

Advaxis to Present at the 27th Annual ROTH Conference

Read More

Advaxis to Present at the Cowen and Company 35th Annual Health Care Conference

Read More

Advaxis to Present at International Anal Neoplasia Society Scientific Meeting 2015

Read More

Advaxis Completes $23 Million Financing

Read More

Advaxis Appoints Mayo Pujols Vice President, Manufacturing

Read More